Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 16;14(6):1517. doi: 10.3390/cancers14061517

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Venn diagram of serum miRs related to the presence of COLO357PL and MDA-MB-231 xenograft tumors, and serum miRs related to the short-term treatment with the FGFR inhibitor, PD173074. The expression levels of 352 serum miRs in COLO357PL (green) and 88 serum miRs in the MDA-MB-231 (magenta) xenograft mouse model were analyzed by qPCR and normalized for respective median Ct value. miRs with Ct < 30 that were changed by ≥2-fold are presented. Additionally, serum miRs changes after short-term treatment with PD173074 (blue) in both xenograft models are presented. Fold changes in serum miR expression after the PD173074 treatment are presented for every tumor-related miR with Ct < 30, as well as those that are ≥2-fold deregulated after PD173074 treatment.